EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives

Klara Andrzejczak iD, Emilia Kucharczyk iD, Matylda Korgiel iD, Justyna Drozdowska iD, Joanna Maj, Małgorzata Ponikowska

Pharmaceutics · 15.05.2026 · 18 (5) · 605

DOI: 10.3390/pharmaceutics18050605 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 15.05.2026. Verfasst von Klara Andrzejczak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wroclaw Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic inflammatory skin diseases, including psoriasis, hidradenitis suppurativa (HS), and atopic dermatitis (AD), are increasingly recognized as systemic disorders associated with chronic immune dysregulation. Growing evidence supports their links with metabolic disorders, reflected in heightened interest in therapeutic strategies targeting the immunometabolic axis. This review summarizes current knowledge on the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the regulation of immune and metabolic processes in chronic inflammatory skin diseases, with particular emphasis on molecular mechanisms and available experimental and clinical data. GLP-1RAs, widely used in the treatment of type 2 diabetes and obesity, may also exhibit anti-inflammatory and immunomodulatory properties beyond their classical metabolic effects. GLP-1 signalling can influence keratinocyte function, immune cell activity, and wound healing. Furthermore, it modulates multiple intracellular signalling pathways, including cAMP/PKA, AMPK, PI3K/Akt, and NF-κB, as well as immune axes such as IL-23/Th17/IL-17 and inflammasome-related signalling. Available evidence suggests that GLP-1RAs may reduce inflammation and disease activity in selected inflammatory dermatoses. However, current evidence remains limited and is based primarily on experimental studies, case reports, and small-scale observational studies. Further well-designed clinical trials are needed to better define the therapeutic potential of GLP-1RAs and their role in dermatological practice.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptoratopic dermatitischronic inflammatory skin diseasesglucagon-like peptide-1 receptor agonists (GLP-1RAs)hidradenitis suppurativaimmunometabolisminflammationpsoriasis

Autor:innen und Institutionen

  • Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.
  • University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland.

ORCID-Profile: Klara Andrzejczak, Emilia Kucharczyk, Matylda Korgiel, Justyna Drozdowska

Förderung

  • Wroclaw Medical University

Zitieren

APA

Andrzejczak, K., Kucharczyk, E., Korgiel, M., Drozdowska, J., Maj, J., & Ponikowska, M. (2026). GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives. Pharmaceutics, 18(5), 605. https://doi.org/10.3390/pharmaceutics18050605

Vancouver

Andrzejczak K, Kucharczyk E, Korgiel M, Drozdowska J, Maj J, Ponikowska M. GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives. Pharmaceutics. 2026;18(5):605. doi:10.3390/pharmaceutics18050605

BibTeX
@article{Andrzejczak2026,
  author = {Andrzejczak, Klara and Kucharczyk, Emilia and Korgiel, Matylda and Drozdowska, Justyna and Maj, Joanna and Ponikowska, Małgorzata},
  title = {GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {5},
  pages = {605},
  doi = {10.3390/pharmaceutics18050605}
}
Kostenlos starten →